Detalhe da pesquisa
1.
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
N Engl J Med
; 386(4): 351-363, 2022 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34904799
2.
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial.
Blood
; 141(16): 1971-1981, 2023 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36626583
3.
Analysis of ventricular arrhythmias and sudden death from prospective, randomized clinical trials of acalabrutinib.
Br J Haematol
; 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38634256
4.
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Haematologica
; 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38268449
5.
A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib.
Haematologica
; 107(11): 2630-2640, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35443563
6.
The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study.
Haematologica
; 107(1): 134-142, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33327712
7.
Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients.
Haematologica
; 107(6): 1335-1346, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34587719
8.
Analytical similarity as base for rituximab biosimilars in lymphoid malignancies in the clinic: a PF-05280586 case study.
Future Oncol
; 18(12): 1499-1510, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35068186
9.
Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review.
Future Oncol
; 18(26): 2943-2966, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35856239
10.
MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Future Oncol
; 18(33): 3689-3699, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36102212
11.
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Lancet
; 395(10232): 1278-1291, 2020 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32305093
12.
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
Haematologica
; 106(9): 2364-2373, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33730844
13.
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
Lancet Oncol
; 20(7): 998-1010, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31101489
14.
An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
Br J Haematol
; 184(2): 215-222, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30183069
15.
Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.
Blood
; 127(1): 79-86, 2016 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26472752
16.
Monitoring and Management of Toxicities of Novel B Cell Signaling Agents.
Curr Oncol Rep
; 20(6): 49, 2018 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29644450
17.
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
Lancet Oncol
; 18(3): 297-311, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28139405
18.
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.
Br J Haematol
; 176(3): 412-420, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27982425
19.
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
N Engl J Med
; 370(11): 997-1007, 2014 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24450857
20.
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.
Blood
; 126(26): 2798-804, 2015 Dec 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-26377597